Sign In
Buy DOCS
$20.91
-0.330 (-1.55%)
At Close: Jul 31, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
04:45pm, Tuesday, 26'th May 2026
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. (“Doximity” or the “Company”) (NYSE: DOCS). Such investors are advis
Doximity Stock Just Got Crushed. Is This a Rare Chance to Buy a High-Quality Growth Company on Sale?
12:30pm, Sunday, 24'th May 2026
The market seems concerned that AI could replace some of Doximity's solutions for the medical community. However, its powerful ecosystem, paired with complex regulations, shouldn't be easily disrupted
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCS
06:40pm, Thursday, 21'st May 2026
NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS). Such investors are advised to contact
Doximity to Present at the William Blair 46th Annual Growth Stock Conference
04:01pm, Thursday, 21'st May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that Jeff Tangney, co-founder and CEO, will present at the Wil
OPRX Boosts DSP Revenue Potential While Navigating Near-Term Headwinds
09:50am, Wednesday, 20'th May 2026
OptimizeRx expands DSP integration to unlock scalable EHR ad campaigns and boost inventory use despite lowering 2026 revenue guidance.
Dr Martens profits jump as turnaround gains grip
02:53am, Tuesday, 19'th May 2026
Dr Martens PLC (LSE:DOCS) returned to profit growth last year as the bootmaker tightened discounting, improved margins and pushed ahead with a turnaround centred on higher-quality sales. The FTSE 250-
Forget Hims. Its CEO Dumped 436,000 Shares Before a 1,266% Earnings Miss.
09:22am, Monday, 18'th May 2026
Hims & Hers (NYSE:HIMS) is dominating headlines this week because the GLP-1 darling just delivered one of the ugliest quarters in the telehealth sector's short history, and bargain hunters are circlin
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
DOCS vs. HIMS: Which Stock Is the Better Value Option?
12:40pm, Friday, 15'th May 2026
Investors interested in stocks from the Medical Info Systems sector have probably already heard of Doximity (DOCS) and Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best opt
DOCS Teams Up With Aledade to Bring Clinical AI to Value-Based Care
12:36pm, Friday, 15'th May 2026
Doximity teams with Aledade to bring AI-powered documentation and clinical search tools into physician workflows and value-based care settings.
Doximity Earnings: Strong AI Signals, But Monetization Still Pending
12:20pm, Friday, 15'th May 2026
Doximity, Inc. delivered mixed FY26 results, with solid revenue growth but margin compression and a cautious near-term outlook. AI-driven engagement is accelerating, with rapid adoption of clinical to
Down 25.7% in 4 Weeks, Here's Why Doximity (DOCS) Looks Ripe for a Turnaround
10:37am, Friday, 15'th May 2026
Doximity (DOCS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Pre-Market Stock Futures: Futures are trading sharply lower as we get set to end one of the most exciting weeks on Wall Street in 25 years. Positive meetings in China with President Trump, who brought
Doximity Stock Falls on Q4 Earnings Miss, Revenues Beat, Margins Down
12:45pm, Thursday, 14'th May 2026
DOCS' revenues top estimates as AI tool adoption and large customer growth fuel engagement despite weaker earnings and margin pressure.
Doximity Flags Pharma Ad Market Weakness
12:09pm, Thursday, 14'th May 2026
Doximity Inc. (NYSE:DOCS) shares are down on Thursday after the company reported mixed results for the fourth quarter and issued soft annual guidance.
